{"title":"伊鲁替尼单药治疗结外边缘区b细胞淋巴瘤","authors":"Yu.V. Batukhtina, R. Zukov","doi":"10.33978/2307-3586-2022-18-13-34-37","DOIUrl":null,"url":null,"abstract":"The article presents a clinical case of treatment of orbital B-cell lymphoma of the extranodal marginal zone. This case report demonstrates the safety and efficacy of ibrutinib monotherapy in patients with relapsed/refractory LMZ previously reported in the PCYC-1121 study. Research and clinical evidence support the use of ibrutinib monotherapy as an alternative to chemotherapy in this patient population with a favorable benefit-risk profile and a convenient once-daily regimen.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"26 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Monotherapy with Ibrutinib in B-cell Lymphoma of the Extranodal Marginal Zone\",\"authors\":\"Yu.V. Batukhtina, R. Zukov\",\"doi\":\"10.33978/2307-3586-2022-18-13-34-37\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The article presents a clinical case of treatment of orbital B-cell lymphoma of the extranodal marginal zone. This case report demonstrates the safety and efficacy of ibrutinib monotherapy in patients with relapsed/refractory LMZ previously reported in the PCYC-1121 study. Research and clinical evidence support the use of ibrutinib monotherapy as an alternative to chemotherapy in this patient population with a favorable benefit-risk profile and a convenient once-daily regimen.\",\"PeriodicalId\":11400,\"journal\":{\"name\":\"Effective Pharmacotherapy\",\"volume\":\"26 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Effective Pharmacotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33978/2307-3586-2022-18-13-34-37\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Effective Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33978/2307-3586-2022-18-13-34-37","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Monotherapy with Ibrutinib in B-cell Lymphoma of the Extranodal Marginal Zone
The article presents a clinical case of treatment of orbital B-cell lymphoma of the extranodal marginal zone. This case report demonstrates the safety and efficacy of ibrutinib monotherapy in patients with relapsed/refractory LMZ previously reported in the PCYC-1121 study. Research and clinical evidence support the use of ibrutinib monotherapy as an alternative to chemotherapy in this patient population with a favorable benefit-risk profile and a convenient once-daily regimen.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
